

Table SI. Characteristics of patients with colorectal cancer with or without SPM.

Characteristics	Total (n=88)	SPM (n=5)	Without SPM (n=83)	P-value
Age, years, mean \pm SD	58.91 \pm 10.87	64.00 \pm 7.91	58.60 \pm 10.99	0.2833
Sex, n (%)				0.6515
Female	28 (31.82)	2 (40.00)	26 (31.33)	
Male	60 (68.18)	3 (60.00)	57 (68.67)	
Cigarette and alcohol consumption, n (%)				
None	23 (10.60)	2 (40.00)	29 (34.94)	
C ₂₀	26 (11.98)	1 (20.00)	8 (9.64)	0.5450
C ₂₀ A ₂₀	41 (18.89)	2 (40.00)	15 (18.07)	0.6073
Family history of malignancy, n (%)	2 (16.59)	0	2 (2.41)	NA
Hypertension, n (%)	17 (19.32)	3 (60.00)	14 (16.87)	0.0476
Diabetes, n (%)	4 (4.55)	1 (20.00)	3 (3.61)	0.212
Biliary tract disease, n (%)	11 (12.50)	1 (20.00)	10 (12.05)	0.4957
TNM stage, n (%)				0.3826
\leq IIB	35 (39.77)	3 (60.00)	32 (18.45)	
\geq IIIA	53 (60.23)	2 (40.00)	51 (81.55)	
Treatment				
RT	2 (2.27)	0	2 (2.41)	
CT	4 (4.55)	1 (20.00)	3 (3.61)	NA
RCT	7 (7.96)	2 (40.00)	5 (6.02)	0.6431
SCT	23 (26.14)	0	23 (27.71)	
SRT	3 (3.41)	0	3 (3.61)	NA
SRCT	48 (54.55)	2 (40.00)	46 (55.42)	NA
Median survival in months, n (beyond IIIA, %)	43, 13 (14.77)	113, 4 (80.00)	34, 9 (10.84)	0.0094
Succumbed to SPM, n (%)	4 (4.55)	4 (80.00)	NA	NA
FPM-SPM time interval, months	NA	125.8 \pm 77.28	NA	NA
Survival with SPM, months, mean \pm SD	NA	21.00 \pm 25.02	NA	NA
Pathology of SPM, n (%)	Gastrointestinal AD, 2 (2.27); SCLC, 3 (3.41)	Gastrointestinal AD, 2 (40.00); SCLC, 3 (60.00)	NA	NA

SPM, second primary malignancy; C₂₀, 20-29 years regular cigarette consumption; C₂₀A₂₀, 20-29 years regular cigarette and alcohol consumption; RT, radiotherapy; CT, chemotherapy; RCT, radiochemotherapy; SCT, post-surgical CT; SRT, post-surgical RT; SRCT, post-surgical RCT; FPM, first primary malignancy; AD, adenocarcinoma; SCLC, small cell lung cancer; NA, not applicable.

Table SII. Characteristics of patients with stomach cancer with or without SPM.

Characteristics	Total (n=39)	SPM (n=7)	Without SPM (n=32)	P-value
Age, years, mean \pm SD	56.93 \pm 14.50	63.43 \pm 11.39	55.59 \pm 14.84	0.1962
Sex, n (%)				0.4026
Female	12 (30.77)	1 (14.29)	11 (34.38)	
Male	27 (69.23)	6 (85.71)	21 (65.62)	
Cigarette and alcohol consumption, n (%)				>0.9999
None	19 (48.72)	5 (71.43)	14 (41.17)	
C ₃₀ A ₃₀	7 (17.95)	1 (14.29)	6 (17.65)	
Family history of malignancy, n (%)	5 (12.82)	0	5 (14.71)	NA
Diabetes, n (%)	7 (17.95)	1 (14.29)	6 (10.91)	>0.9999
Biliary tract disease, n (%)	4 (10.26)	1 (14.29)	3 (8.82)	0.5421
TNM stage, n (%)				0.6857
\leq IIB	14 (45.00)	3 (42.86)	11 (34.38)	
\geq IIIA	33 (55.00)	4 (57.14)	21 (65.62)	
Median survival in months, n (beyond IIIA, %)	21.5, 36 (60.00)	42.5, 4 (57.14)	21.5, 32 (58.18)	0.7364
Succumbed to SPM, n (%)	4 (6.67)	4 (57.24)	NA	NA
FPM-SPM time interval, months	NA	99 (LUSC)	NA	NA
Survival with SPM, months, mean \pm SD	NA	12 (LUSC)	NA	NA
Pathology of SPM, n (%)	GM, 2 (3.33); LUSC, 1 (1.67); thyroid cancer, 2 (3.33)	GM, 2 (40.00); LUSC, 1 (20.00); thyroid cancer, 2 (40.00)	NA	NA

SPM, second primary malignancy; C₃₀A₃₀, 30-39 years of regular cigarette and alcohol consumption; FPM, first primary malignancy; LUSC, lung squamous cell carcinoma; GM, gastrointestinal malignancy; NA, not applicable.

Table SIII. Characteristics of patients with esophageal cancer with or without SPM.

Characteristics	Total (n=60)	SPM (n=5)	Without SPM (n=55)	P-value
Age, years, mean \pm SD	63.70 \pm 9.42	65.00 \pm 10.24	63.56 \pm 9.42	0.726
Sex, n (%)				0.4746
Female	7 (11.48)	1 (20.00)	6 (10.91)	
Male	53 (88.52)	4 (80.00)	49 (89.09)	
Cigarette and alcohol consumption, n (%)				0.287
None	15 (25.00)	3 (60.00)	12 (21.82)	
C ₃₀ A ₃₀	21 (35.00)	1 (20.00)	20 (36.36)	
Family history of malignancy, n (%)	11 (18.03)	1 (20.00)	10 (18.18)	>0.9999
Diabetes, n (%)	7 (11.48)	1 (20.00)	6 (10.91)	0.4746
Biliary tract disease, n (%)	4 (6.56)	1 (20.00)	3 (5.46)	0.3006
TNM stage				0.6494
\leq IIB	27 (45.00)	3 (60.00)	24 (43.64)	
\geq IIIA	33 (55.00)	2 (40.00)	31 (56.36)	
Median survival in months, n (beyond IIIA, %)	21.5, 36 (60.00)	42.5, 4 (80.00)	21.5, 32 (58.18)	0.7364
Succumbed to SPM, n (%)	4 (6.67)	4 (80.00)	NA	NA
FPM-SPM time interval, months	NA	99 (LUSC)	NA	NA
Survival with SPM, months, mean \pm SD	NA	12 (LUSC)	NA	NA
Pathology of SPM, n (%)	GIST, 2 (3.33); LUSC, 1 (1.67); thyroid cancer, 2 (3.33)	GIST, 2 (40.00); LUSC, 1 (20.00); thyroid cancer, 2 (40.00)	NA	NA

SPM, second primary malignancy; C₃₀A₃₀, 30-39 years of regular cigarette and alcohol consumption; FPM, first primary malignancy; LUSC, lung squamous cell carcinoma; GIST, gastrointestinal stromal tumor; NA, not applicable.

Table SIV. Characteristics of patients with lung cancer without SPM.

Cancer type	Age at diagnosis (years)			Survival	
	Number	Mean±SD	Range	Number	Median (months)
LUSC	109	60.50±8.81	34-77	102	17
LUAD	96	58.66±9.13	31-74	82	21
SCLC	103	59.87±8.69	42-84	98	13.5
LCLC	6	51.00±9.57	43-67	6	14
Adenosquamous	12	56.50±7.40	48-74	12	27.5
Other types (neuroendocrine,carci noid, sarcomatoid)	10	62.40±8.86	50-75	10	13.5

SPM, second primary malignancy; LUSC, lung squamous cell carcinoma; LUAD, lung adenocarcinoma; SCLC, small cell lung carcinoma; LCLC, large cell lung carcinoma.

Table SV. Characteristics of patients with non-small cell lung cancer with or without SPM.

Characteristics	LUSC			LUAD		
	SPM (n=4)	Without SPM (n=110)	P-value	SPM (n=7)	Without SPM (n=96)	P-value
Age, years, mean \pm SD	65.00 \pm 4.12	60.50 \pm 8.81	0.259	58.29 \pm 11.66	58.66 \pm 9.13	0.7395
Sex, n (%)			>0.9999			0.4391
Female	0	3 (2.73)		4 (57.14)	38 (39.58)	
Male	4 (100)	107 (97.27)		3 (42.86)	58 (60.42)	
Cigarette and alcohol consumption, n (%)						
None	0	9 (8.18)		4 (57.14)	10 (10.42)	
C ₃₀	2 (50)	22 (20.00)	>0.9999	0	12 (12.50)	0.1001
C ₃₀ A ₃₀	2 (50)	27 (24.55)	>0.9999	3 (42.86)	9 (9.38)	>0.9999
Treatment						
RT	0	7 (6.36)	>0.9999	1 (14.29)	0	0.1000
CT	0	15 (13.64)	0.4920	1 (14.29)	16 (16.67)	>0.9999
RCT	2 (50)	17 (15.45)		2 (28.57)	27 (28.13)	
ST	1 (25)	0		0	0	
SCT	1 (25)	10 (9.09)	0.2973	0	5 (5.21)	0.0476
SRT	1 (25)	21 (19.09)	0.4583	0	11 (11.46)	0.0128
SRCT	0	26 (23.64)		2 (28.57)	0	
Family history of malignancy, n (%)	1 (25)	23 (20.91)	>0.9999	3 (42.86)	9 (9.38)	0.0329
Diabetes, n (%)	1	5 (4.55)	0.1969	0	6 (6.25)	>0.9999
Hypertension, n (%)	0	14 (12.73)	>0.9999	0	15 (15.63)	0.5897
Thyroid dysfunction, n (%)	0	1 (0.91)	>0.9999	0	2 (2.08)	>0.9999
Biliary tract disease, n (%)	1 (25)	4 (3.64)	0.1663	1 (14.29)	9 (9.38)	0.5219
TNM stage, n (%)			0.2523			>0.9999
\leq IIB	2 (50)	26 (23.64)		3 (42.86)	37 (38.54)	
\geq IIIA	2 (50)	84 (76.36)		4 (57.14)	59 (61.46)	
FPM-SPM interval, months	60.20 \pm 22.85	NA		44.71 \pm 52.97	NA	NA
Median survival in months, n (beyond IIIA, %)	81, 3 (60)	17, 99 (90)	0.038	29, 6 (85.71)	21, 86 (89.58)	0.1334
Succumbed to SPM, n (%)	4 (80)	NA	NA	1 (14.29)	NA	NA
Survival with SPM, months, mean \pm SD	8.50 \pm 4.80	NA	NA	14.43 \pm 13.55	NA	NA
Pathology of	ESCC, 3 (60);	NA	NA	Gastrointestinal	NA	NA

SPM, n (%)	SCLC, 2 (40)			AD, 5 (71.43); breast cancer, 1 (14.29); neurogenic tumor, 1 (14.29)		
------------	--------------	--	--	---	--	--

SPM, second primary malignancy; LUSC, lung squamous cell carcinoma; LUAD, lung adenocarcinoma; C₃₀, regular cigarette consumption for 30-39 years; C₃₀A₃₀ regular cigarette and alcohol consumption for 30-39 years; RT, radiotherapy; CT, chemotherapy; RCT, radiochemotherapy; ST, surgical resection; SRT post-surgical RT; SCT, post-surgical CT; SRCT, post-surgical RCT; ESCC, esophageal squamous cell carcinoma; SCLC, small cell lung cancer; AD, adenocarcinoma; NA, not applicable.